Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05501223

Enrollment

Registered

2022-08-15

Start date

2020-11-01

Completion date

2022-11-30

Last updated

2022-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypharmacy

Keywords

Polypharmacy

Brief summary

Aiming to reduce polypharmacy in patients with type 2 diabetes by using physician-initiated medication reviews.

Detailed description

Patients will be randomised to either standard care(annual visit at outpatient clinic) or standard care plus an intervention. The intervention is a medication consultation of 30-60 minutes that consist of a medication review and increased cross-sectoral communication. Follow-up is 6 months. Primary outcome are number of medications used, secondary outcomes are health related quality of life and persistance of medication changes.

Interventions

OTHERMedication review

30-60 minutes extra consultation regarding the patients drugs

OTHERStandard care

Standard care i.e. visit at the Dept. of Endocrinology.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. DM2 2. 12 medications in the central prescription list

Exclusion criteria

1. inability to give written consent (e.g., inability to understand the intervention or language barriers); 2. active cancer or palliative treatment; 3. admitted to the hospital.

Design outcomes

Primary

Measure	Time frame	Description
Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.	6 months	The no. of medications used at baseline will be compared to the no. of medications used at follow-up. This will result in a rate i.e. no. at follow-up/no. at baseline which can be compared between groups resulting in a rate ratio. Medication usage is determined by number of medications listed in the central prescription list.

Secondary

Measure	Time frame	Description
EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.	6 months	Health related quality of life measured by EQ5D index score using Danish value sets (ranging from -0.7 (worst quality of life) to 1 (best quality of life)).

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026